Shareholders meeting

Date: 4th September, 2026 The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001. Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Sub: Notice of 38th Annual General Meeting and Annual Report for the FY 2025‐2026. We wish to inform you that the 38th Annual General Meeting (AGM) of the Company is scheduled to be held on Tuesday, 29th September 2026, at 10:30 a.m (IST) through Video Conferencing (VC)/ Other Audio-Visual Means. Pursuant to Regulation 34 of SEBI (LODR) Regulations, 2015, please find enclosed Notice convening the 38th AGM of the Company along with Annual Report for the financial year 2025- 26, being dispatched to the Members who have registered their e-mail addresses with the Company/ Registrar and Transfer Agent/ Depositories. In addition, pursuant to Regulation 36(1)(b) of the SEBI (LODR) Regulations, 2015, a letter is also being sent to the Members whose email addresses are not registered, providing the web-link where the Annual Report is uploaded on website. The said documents are also available on the website of the Company at https://smspharma.com/wp-content/uploads/2026/09/2026.pdf The Company is pleased to provide its members with the facility to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means. Further the following details for the purpose of ensuing AGM: Record Date for Dividend Tuesday, 22nd September, 2026 Cut-off Date for e-voting eligibility and Tuesday, 22nd September, 2026 attending AGM Book Closure Dates Wednesday, 23rd September, 2026 to Tuesday, 29th September, 2026 (both days inclusive) The Remote e-voting Start date and time Friday, 25th September, 2026, 9.00 a.m. (IST) The Remote e-voting end date and time Monday 28th September, 2026, 5.00 p.m. (IST) Please take the above intimation on your records. Thanking you Yours faithfully For SMS Pharmaceuticals Limited Thirumalesh Tumma Company Secretary and Compliance Officer Encl: as above Annual Report 2025-26 Driving Progress with a Purpose Innovating. Expanding. Diversifying Driving Progress with a Purpose Innovating. Expanding. Diversifying Every breakthrough begins with a question: what lies beyond the familiar? At SMS Pharmaceuticals, that question has shaped a journey from a single-product operation to a diversified API enterprise serving global pharmaceutical markets. Today, that journey is entering a new chapter, where progress is being shaped by the courage to explore new possibilities, the capacity to scale what works and the vision to venture into what lies ahead. Innovating means looking beyond the familiar, from strengthening our R&D engine and developing differentiated APIs to advancing peptides and laying the foundations for CDMO capabilities. Expanding means building the capacity to turn opportunity into impact, through new manufacturing blocks, stronger integration and investments in future-ready infrastructure. Diversifying means broadening our horizons across therapeutic segments, products and markets, creating multiple pathways for growth. But true progress asks a bigger question than how fast can we grow? It asks what difference can our growth make? For us, the answer lies in advancing healthcare, strengthening partnerships, creating opportunities for our people and communities and growing with greater responsibility towards the resources that sustain us. Innovating. Expanding. Diversifying. Three paths forward, guided by one purpose: to make every step ahead count. 02-37 SMS Pharma is a diversified and Corporate Information integrated pharmaceutical company Corporate Overview specialising in Active Pharmaceutical 04 About Us Ingredients (API) and complex 06 What Sets Us Apart Board of Directors Registrar & Share Transfer Agent Cost Auditors: Intermediates for global customers. 08 Diversified Portfolio M/s. Aarthi Consultants Private Limited M/s. Annapragada & Co., Mr. Ramesh Babu Potluri 10 Our Global Footprint (Formerly :Harshitha Annapragada & Co.,) Chairman and Managing Director 1-2-285, Domalguda, Hyderabad – 500029 12 Chairman’s Message FY26 Highlights Cost Accountants 16 Key Performance Indicators J Mr. Shravan Kudaravalli Ph: 040-27638111 18 Key Milestones 887 Non- Executive Independent Director Off. Add.: Plot No.127 & 128, H.No.11-65, Sai 20 How We Create value Crore Email: aarthiconsultants@gmail.com, Ram Nagar Phase-2, Nadergul, Hyderabad, 22 Stakeholders’ Engagement 13% Mr. Sarvepalli Srinivas info@aarthiconsultants.com Telangana-501510 24 Operational Excellence Revenue YoY Non- Executive Independent Director 29 Research and Development 30 Environmental Stewardship J Dr. Suresh Kumar Gangavarapu Bankers Manufacturing Facilities 32 Driving Inclusive Growth 171 Non-Executive Independent Director State Bank of India Plot.No.24 & 24B and 36 & 37 34 Board of Directors Crore 37 Awards and Accolades Mrs. Shanti Sree Bolleni IDBI Bank Limited S.V. Co-Operative Industrial Estate, EBITDA YoY Non- Executive Independent Director Buchupally, Medchal- Malkajgiri District, RBL Bank Limited Hyderabad, Telangana – 500090, 38-126 J Mr. Vamsi Krishna Potluri 102 Executive Director Export Import Bank of India Ph.No. +91-9100072351/52/54 Crore Statutory Reports 47% (re-appointed w.e.f. 01.07.2025) Axis Bank Limited Email: admin_unit2@smspharma.com PAT YoY Mr. Trilok Potluri Board’s Report 38 Non- Executive, Non-Independent Director Statutory Auditors Management Discussion and Analysis 60 Report on Corporate Governance 69 M/s. Suryanarayana & Suresh, Dr. Sunkara Venkata Satya Shiva Prasad Sy. No. 160, 161, 163 to 168, Business Responsibility and Sustainability Report 94 Non-Executive, Non-Independent Director Chartered Accountants, Kandivalasa Village, Poosapatirega Contents Flat. No: C2, Millennium House # 8-2-601/ Mandal, Vizianagaram District, Andhra Key Managerial Persons B, Road No. 10, Near Zaheer Nagar Cross Pradesh. 535004. Mr. Lakshmi Narayana Tammineedi Road, Banjara Hills, Hyderabad– 500034, Chief Financial Officer Telangana. Ph.No. +91- 08922 – 258051 / 53/54 Email: admin_unit7@smspharma.com Mr. Thirumalesh Tumma Secretarial Auditors Company Secretary & Compliance Officer 127-253 M/s. SVVS & Associates Company Research and Development Secretaries LLP, Centre Registered & Corporate Office Financial Statements Company Secretaries, Sy. No. 186, 189 & 190, Gagillapur Village, 8th Floor, Trendset Jayabheri Connect, Standalone Kondapur, Serilingampally, Ranga Reddy #307, Babukhan Estate, Basheerbagh, Dundigal- Gandimaisamma Mandal, www.smspharma.com Independent Auditors’ Report 127 Dist., Hyderabad-500084, Telangana, India. Hyderabad – 500001, Telangana. Medchal-Malkajgiri District, Hyderabad, Balance Sheet 136 CIN: L24239TG1987PLC008066 Telangana – 500043, Statement of Profit and Loss 137 Internal Auditors Ph.No. + 91 – 8418 – 257337 / 8 Notes to the Financial Statements 141 Contact Details: Scan the QR code to know M/s. Adusumilli and Associates, Consolidated more about the company Independent Auditors’ Report 189 Tel: 040-6985 9999 Chartered Accountants, Email: rnd@smspharma.com Balance Sheet 196 Statement of Profit and Loss 197 Email:info@smspharma.com Off. 7-1-390, Flat. No. 302, Sri Sai Notes to the Financial Statements 201 Residency, Balkampet Main Road, Forward-looking statements Web: www.smspharma.com Hyderabad-500038, Telangana. This report may contain forward-looking statements relating to the Company’s 254-278 expected financial performance, business plans, and prospects. Such statements are generally identified by words like “believe,” “anticipate,” “expect,” “may,” “will,” and similar expressions, and are based on assumptions made in good faith. Notice However, actual results may differ materially from those expressed or implied. The Company undertake [Showing first 8,000 characters — download PDF for full document]